Redefining the Pulvinar Sign in Fabry Disease

References

1. 1.↵
   2. Eng CM,
   3. Germain DP,
   4. Banikazemi M, et al

   . Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539–48 doi:10.1097/01.gim.0000237866.70357.c6 pmid:16980809

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Germain DP

   . Fabry disease. Orphanet J Rare Dis 2010;5:30 doi:10.1186/1750-1172-5-30 pmid:21092187

   CrossRefPubMed
3. 3.↵
   2. Buechner S,
   3. Moretti M,
   4. Burlina AP, et al

   . Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008;79:1249–54 doi:10.1136/jnnp.2008.143693 pmid:18535022

   Abstract/FREE Full Text
4. 4.↵
   2. Kaye EM,
   3. Kolodny EH,
   4. Logigian EL, et al

   . Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23:505–09 doi:10.1002/ana.410230513 pmid:3133979

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Mitsias P,
   3. Levine SR

   . Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8–17 doi:10.1002/ana.410400105 pmid:8687196

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Moore DF,
   3. Kaneski CR,
   4. Askari H, et al

   . The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258–63 doi:10.1016/j.jns.2007.01.053 pmid:17362993

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Fellgiebel A,
   3. Keller I,
   4. Marin D, et al

   . Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009;72:63–68 doi:10.1212/01.wnl.0000338566.54190.8a pmid:19122032

   CrossRefPubMed
8. 8.↵
   2. Fellgiebel A,
   3. Keller I,
   4. Martus P, et al

   . Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 2011;31:294–99 doi:10.1159/000322558 pmid:21196729

   CrossRefPubMed
9. 9.↵
   2. Manara R,
   3. Carlier RY,
   4. Righetto S, et al

   . Basilar artery changes in Fabry disease. AJNR Am J Neuroradiol 2017;38:531–36 doi:10.3174/ajnr.A5069 pmid:28126747

   Abstract/FREE Full Text
10. 10.↵
    2. Putaala J,
    3. Kurkinen M,
    4. Tarvos V, et al

    . Silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke. Neurology 2009;72:1823–29 doi:10.1212/WNL.0b013e3181a711df pmid:19470964

    Abstract/FREE Full Text
11. 11.↵
    2. Uçeyler N,
    3. Homola GA,
    4. Guerrero González H, et al

    . Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. PLoS One 2014;9:e87054 doi:10.1371/journal.pone.0087054 pmid:24475221

    CrossRefPubMed
12. 12.↵
    2. Moore DF,
    3. Ye F,
    4. Schiffmann R, et al

    . Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 2003;24:1096–101 pmid:12812932

    Abstract/FREE Full Text
13. 13.↵
    2. Takanashi J,
    3. Barkovich AJ,
    4. Dillon WP, et al

    . T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol 2003;24:916–21 pmid:12748094

    Abstract/FREE Full Text
14. 14.↵
    2. Fellgiebel A,
    3. Mazanek M,
    4. Whybra C, et al

    . Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. J Neurol 2006;253:780–87 doi:10.1007/s00415-006-0118-y pmid:16511647

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Burlina AP,
    3. Manara R,
    4. Caillaud C, et al

    . The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 2008;255:738–44 doi:10.1007/s00415-008-0786-x pmid:18297328

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Burlina AP,
    3. Politei J,
    4. Cinque S, et al

    . The pulvinar sign in Fabry patients: the first report in female patients. J Neurol 2012;259:1227–28 doi:10.1007/s00415-011-6305-5 pmid:22095041

    CrossRefPubMed
17. 17.↵
    2. Mugikura S,
    3. Takahashi S,
    4. Higano S, et al

    . MR findings in Tay-Sachs disease. J Comput Assist Tomogr 1996;20:551–55 doi:10.1097/00004728-199607000-00009 pmid:8708054

    CrossRefPubMed
18. 18.↵
    2. Kendall BE

    . Disorders of lysosomes, peroxisomes, and mitochondria. AJNR Am J Neuroradiol 1992;13:621–53 pmid:1566722

    FREE Full Text
19. 19.↵
    2. Sahraian MA,
    3. Motamedi M,
    4. Azimi AR, et al

    . Bilateral pulvinar thalamic calcification in a patient with chronic cryptococcal meningitis. Eur J Neurol 2007;14:e1–2 pmid:17388969

    CrossRefPubMed
20. 20.↵
    2. Fazekas F,
    3. Enzinger C,
    4. Schmidt R, et al

    ; SIFAP 1 Investigators. Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event. Stroke 2015;46:1548–53 doi:10.1161/STROKEAHA.114.008548 pmid:25899239

    Abstract/FREE Full Text
21. 21.↵
    2. Kolodny E,
    3. Fellgiebel A,
    4. Hilz MJ, et al

    . Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 2015;46:302–13 doi:10.1161/STROKEAHA.114.006283 pmid:25492902

    FREE Full Text
22. 22.↵
    2. Lee HJ,
    3. Hsu TR,
    4. Hung SC, et al

    . A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation. BMC Neurol 2017;17:25 doi:10.1186/s12883-017-0810-9 pmid:28166746

    CrossRefPubMed
23. 23.↵
    2. Vučić Lovrenčić M,
    3. Radišić Biljak V,
    4. Božičević S, et al

    . Estimating glomerular filtration rate (GFR) in diabetes: the performance of MDRD and CKD-EPI equations in patients with various degrees of albuminuria. Clin Biochem 2012;45:1694–96 doi:10.1016/j.clinbiochem.2012.07.115 pmid:22968085

    CrossRefPubMed
24. 24.↵
    2. Borrelli P,
    3. Palma G,
    4. Tedeschi E, et al

    . Improving signal-to-noise ratio in susceptibility weighted imaging: a novel multicomponent non-local approach. PLoS One 2015;10:e0126835 doi:10.1371/journal.pone.0126835 pmid:26030293

    CrossRefPubMed
25. 25.↵
    2. Palma G,
    3. Comerci M,
    4. Alfano B, et al

    . 3D non-local means denoising via multi-GPU. Fed Conf Comput Sci 2013:495–98
26. 26.↵
    2. Palma G,
    3. Tedeschi E,
    4. Borrelli P, et al

    . A novel multiparametric approach to 3D quantitative MRI of the brain. PLoS One 2015;10:e0134963 doi:10.1371/journal.pone.0134963 pmid:26284778

    CrossRefPubMed
27. 27.↵
    2. Schaltenbrand G,
    3. Wahren W

    . Atlas for Stereotaxy of the Human Brain. 2nd ed. Stuttgart: Thieme; 1977
28. 28.↵
    2. Branton M,
    3. Schiffmann R,
    4. Kopp JB

    . Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002;13(suppl 2):S139–43 pmid:12068026

    FREE Full Text
29. 29.↵
    2. Kanda T,
    3. Ishii K,
    4. Kawaguchi H, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

    CrossRefPubMed
30. 30.↵
    2. Ramalho J,
    3. Semelka RC,
    4. Ramalho M, et al

    . Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 2016;37:1192–98 doi:10.3174/ajnr.A4615 pmid:26659341

    Abstract/FREE Full Text
31. 31.↵
    2. Tedeschi E,
    3. Palma G,
    4. Canna A, et al

    . In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents. Eur Radiol 2016;26:4577–84 doi:10.1007/s00330-016-4245-2 pmid:26905870

    CrossRefPubMed
32. 32.↵
    2. Torvik A,
    3. Lindboe CF,
    4. Rogde S

    . Brain lesions in alcoholics: a neuropathological study with clinical correlations. J Neurol Sci 1982;56:233–48 doi:10.1016/0022-510X(82)90145-9 pmid:7175549

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Antunez E,
    3. Estruch R,
    4. Cardenal C, et al

    . Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. AJR Am J Roentgenol 1998;171:1131–37 doi:10.2214/ajr.171.4.9763009 pmid:9763009

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Zeidler M,
    3. Sellar RJ,
    4. Collie DA, et al

    . The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1412–18 doi:10.1016/S0140-6736(00)02140-1 pmid:10791525

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Keohane C

    . Pulvinar sign on MRI images in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1384 doi:10.1016/S0140-6736(00)02133-4 pmid:10791518

    CrossRefPubMed
36. 36.↵
    2. Ginat DT,
    3. Meyers SP

    . Intracranial lesions with high signal intensity on T1-weighted MR images: differential diagnosis. Radiographics 2012;32:499–516 doi:10.1148/rg.322105761 pmid:22411945

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Renard D,
    3. Castelnovo G,
    4. Campello C, et al

    . Thalamic lesions: a radiological review. Behav Neurol 2014;2014:154631 doi:10.1155/2014/154631 pmid:25100900

    CrossRefPubMed
38. 38.↵
    2. Zaitout Z,
    3. Romanowski C,
    4. Karunasaagarar K, et al

    . A review of pathologies associated with high T1W signal intensity in the basal ganglia on magnetic resonance imaging. Pol J Radiol 2014;79:126–30 doi:10.12659/PJR.890043 pmid:24900164

    CrossRefPubMed
39. 39.↵
    2. Moore DF,
    3. Altarescu G,
    4. Barker WC, et al

    . White matter lesions in Fabry disease occur in ‘prior’ selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003;62:231–40 doi:10.1016/j.brainresbull.2003.09.021 pmid:14698356

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Igarashi T,
    3. Sakuraba H,
    4. Suzuki Y

    . Activation of platelet function in Fabry's disease. Am J Hematol 1986;22:63–67 doi:10.1002/ajh.2830220110 pmid:3006478

    CrossRefPubMedWeb of Science
41. 41.↵
    2. DeGraba T,
    3. Azhar S,
    4. Dignat-George F, et al

    . Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000;47:229–33 pmid:10665494

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Deoni SC

    . Quantitative relaxometry of the brain. Top Magn Reson Imaging 2010;21:101–13 doi:10.1097/RMR.0b013e31821e56d8 pmid:21613875

    CrossRefPubMed